Adagene Inc - ADR Stock

$1.55

5.63% today

Nasdaq, Apr 04, 07:23 pm CET

ISIN

US0053291078

Symbol

ADAG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Adagene Inc - ADR Stock price

$1.64

-28.35 94.53% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

+0.00 0.00%

ISIN

US0053291078

Symbol

ADAG

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$77.26m
Enterprise Value	$10.56m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	105.60
P/S ratio (TTM) P/S ratio	772.60
P/B ratio (TTM) P/B ratio	1.53
Revenue growth (TTM) Revenue growth	-99.43%
Revenue (TTM) Revenue	$100.00k
EBIT (operating result TTM) EBIT	$-35.91m
Free Cash Flow (TTM) Free Cash Flow	$-29.66m
EPS (TTM) EPS	$-0.74
P/E forward	negative
P/S forward	2,317.82
EV/Sales forward	316.80
Short interest	0.03%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Adagene Inc - ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Adagene Inc - ADR forecast:

1x Buy

33%

2x Hold

67%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Adagene Inc - ADR forecast:

Buy

33%

Hold

67%

Analyst Estimates with Stock Price Targets

Financial data from Adagene Inc - ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	0.10 0.10	99% 99% 100%
- Direct Costs	0.93 0.93	- 930%
Gross Profit	-0.82 -0.82	- -820%
- Selling and Administrative Expenses	6.34 6.34	28% 28% 6,340%
- Research and Development Expense	28 28	25% 25% 27,820%
EBITDA	-35 -35	- -34,980%
- Depreciation and Amortization	0.93 0.93	- 930%
EBIT (Operating Income) EBIT	-36 -36	30% 30% -35,906%
Net Profit	-33 -33	73% 73% -33,380%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adagene Inc - ADR Stock News

Neutral

GlobeNewsWire

●

11 days ago

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses

Neutral

GlobeNewsWire

●

22 days ago

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The summit, designed for all-size pharma/biotech companies, academia and investors seeking to e...

Neutral

GlobeNewsWire

●

29 days ago

Adagene to Present at Leerink's Global Healthcare Conference 2025

SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink's Global...

More Adagene Inc - ADR News

Company Profile

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Head office	Cayman Islands
CEO	Peizhi Luo
Employees	138
Founded	2011
Website	www.adagene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now